Literature DB >> 19100766

Physiological and pharmacological implications of beta-arrestin regulation.

Cullen L Schmid1, Laura M Bohn.   

Abstract

G protein-coupled receptor-targeted drug discovery as well as "compound reassessment" requires the utilization of diverse screens to determine agonist efficacies and potencies beyond the scope of ligand binding and G protein coupling. Such efforts have arisen from extensive studies, both in cellular and animal models, demonstrating that these seven transmembrane domain-spanning, G protein-coupled receptors may engage in more diverse functions than their name suggests and particular focus is drawn to their interactions with beta-arrestins (betaarrestins). As regulators, betaarrestins are involved in dampening G protein-coupling pathways. betaArrestins can also play pro-signaling roles in receptor mediated events and the coupling of receptors to betaarrestins may be as important as their potential to couple to G proteins in the physiological setting. In the last decade, the development of betaarrestin deficient mouse models has allowed for the assessment of the contribution of individual betaarrestins to receptor function in vivo. This review will discuss the current literature that implicates betaarrestins in receptor function in respect to physiological and behavioral responses observed in the live animal model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19100766      PMCID: PMC2656564          DOI: 10.1016/j.pharmthera.2008.11.005

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  77 in total

1.  A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation.

Authors:  L S Barak; S S Ferguson; J Zhang; M G Caron
Journal:  J Biol Chem       Date:  1997-10-31       Impact factor: 5.157

Review 2.  G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization.

Authors:  R J Lefkowitz
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

3.  Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness.

Authors:  J Zhang; S S Ferguson; L S Barak; S R Bodduluri; S A Laporte; P Y Law; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

4.  Morphine-activated opioid receptors elude desensitization by beta-arrestin.

Authors:  J L Whistler; M von Zastrow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 5.  Desensitization of G protein-coupled receptors.

Authors:  N J Freedman; R J Lefkowitz
Journal:  Recent Prog Horm Res       Date:  1996

Review 6.  Pharmacology and mechanisms of opioid analgesic activity.

Authors:  T L Yaksh
Journal:  Acta Anaesthesiol Scand       Date:  1997-01       Impact factor: 2.105

7.  beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation.

Authors:  D A Conner; M A Mathier; R M Mortensen; M Christe; S F Vatner; C E Seidman; J G Seidman
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

8.  Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine.

Authors:  D Crespi; T Mennini; M Gobbi
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

9.  Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.

Authors:  S M Sorensen; J H Kehne; G M Fadayel; T M Humphreys; H J Ketteler; C K Sullivan; V L Taylor; C J Schmidt
Journal:  J Pharmacol Exp Ther       Date:  1993-08       Impact factor: 4.030

10.  The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine.

Authors:  C J Schmidt; C K Black; V L Taylor; G M Fadayel; T M Humphreys; T R Nieduzak; S M Sorensen
Journal:  Eur J Pharmacol       Date:  1992-09-22       Impact factor: 4.432

View more
  39 in total

Review 1.  Serotonin receptor signaling and regulation via β-arrestins.

Authors:  Laura M Bohn; Cullen L Schmid
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-10-07       Impact factor: 8.250

2.  Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo.

Authors:  Cullen L Schmid; Laura M Bohn
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 4.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Ligand- and cell-dependent determinants of internalization and cAMP modulation by delta opioid receptor (DOR) agonists.

Authors:  Iness Charfi; Karim Nagi; Ouissame Mnie-Filali; Dominic Thibault; Gianfranco Balboni; Peter W Schiller; Louis-Eric Trudeau; Graciela Pineyro
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

Review 6.  Endosomes: a legitimate platform for the signaling train.

Authors:  Jane E Murphy; Benjamin E Padilla; Burcu Hasdemir; Graeme S Cottrell; Nigel W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

Review 7.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

8.  Noradrenergic antidepressant responses to desipramine in vivo are reciprocally regulated by arrestin3 and spinophilin.

Authors:  Christopher Cottingham; Xiaohua Li; Qin Wang
Journal:  Neuropharmacology       Date:  2012-02-19       Impact factor: 5.250

Review 9.  Neoclerodanes as atypical opioid receptor ligands.

Authors:  Thomas E Prisinzano
Journal:  J Med Chem       Date:  2013-04-18       Impact factor: 7.446

Review 10.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.